Navigation Links
Ceregene Presents Long-term Follow-up From Phase 1 Trial of CERE-120 in Parkinson's Disease
Date:12/12/2007

Data Suggest Continued Improvement in Motor Function at 24 Months

SAN DIEGO, Dec. 12 /PRNewswire/ -- Ceregene, Inc. today presented long-term follow-up data from a Phase 1 clinical trial of CERE-120 in 12 patients with advanced Parkinson's disease. CERE-120 uses gene therapy to deliver the neural growth factor neurturin to the major area of neurodegeneration that occurs in the brains of Parkinson's disease patients. Long-term follow up assessments at 18 and 24 months post treatment, suggest a sustained reduction in Parkinson's symptoms. It was previously reported that an average of 36 percent (p<0.001) reduction in Parkinson's symptoms was seen 12 months after CERE-120 administration. Of the 12 subjects treated, nine had shown a clinically meaningful reduction in symptoms at 12 months, and the mean improvement of these 'responders' at 12 months was 46 percent. Today it was reported that the eight evaluable responders exhibited a persistent mean improvement in symptoms of 52 percent at their longest time of follow-up (24 months for low-dose cohort and 18 months for high-dose cohort). More specifically, there was a statistically significant improvement in the primary endpoint compared to baseline (p<0.001) defined as the reduction in Parkinson's symptoms as measured by the Unified Parkinson's Disease Rating Scale (UPDRS) motor "off" score ("motor off" meaning patients were off Parkinson's medication at evaluation time). CERE-120 continues to appear safe and well-tolerated, with no treatment-related or surgically-related serious adverse events reported for any of these patients. These data were presented today at the World Congress of Parkinson's Disease by Raymond T. Bartus, Ph.D., Ceregene's executive vice president of clinical and preclinical R&D and chief operating officer.

The Phase 1 trial was an open-label study conducted in 12 patients with advanced Parkinson's disease at two clinical trial sites -- University of California, San Francisco
'/>"/>

SOURCE Ceregene, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
3. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
8. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
9. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
10. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
11. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... 3, 2015  Cyberonics, Inc. (NASDAQ: CYBX ... treatment and management of epilepsy, today announced it will ... March 11, 2015, in Miami . ... Chief Executive Officer, will speak at 1:05 PM Eastern ... chat format, and no formal materials will be presented.  ...
(Date:3/3/2015)... March 3, 2015 Today, the Partnership ... by America,s biopharmaceutical research companies, unveiled a redesigned ... to provide patients and caregivers with faster, easier ... and private patient assistance programs. ... a platform to engage, educate and empower patients ...
(Date:3/3/2015)... BETHESDA, Md. , March 3, 2015 /PRNewswire/-- ViaCyte, ... stem cell-derived islet replacement therapy for the treatment of ... Dr. Eugene Brandon , Director of Strategic Relations ... annual summit showcases the latest in type 1 diabetes ... presentation are as follows: , , , ...
Breaking Medicine Technology:Partnership for Prescription Assistance Relaunches Website with New Features for Patients and Caregivers 2ViaCyte to Present at JDRF TypeOneNation Research Summit 2
... Sentry Data Systems, Inc. , a healthcare business intelligence ... team of 340B experts preparing to attend the 8th Annual ... 2 in San Diego, California. Sentry is proud to be ... The conference will focus on the increased scrutiny ...
... 21, 2012  Apelon, Inc., an international provider of ... announce a major new release (4.0) of its ... open source terminology management platform. Based on extensive ... new release features significant usability enhancements, new methods ...
Cached Medicine Technology:Sentry Brings Expertise to 340B Coalition Winter Conference 2Apelon Introduces Distributed Terminology System 4.0 2
(Date:3/4/2015)... 04, 2015 The medical device landscape ... management forgot – or ignored or didn't know – ... market based on physician input before proceeding to design ... specifically, founders – become so enamored of an innovative ... Will physicians use the device?” says Dr. Kathryn ...
(Date:3/3/2015)... 2015 On February 24, 2015, a ... United States District Court for the Northern District of ... well as insurance companies Balboa, QBE, and Newport Management. ... No. 3:14-cv-152.) , The Plaintiff, a Ms. Dolores Gorsuch, ... force her to buy too much insurance at rates ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 Longtime parent ... with CARE Surrogacy Center for a candid ... originally appearing online is an exhilarating revelation of his ... have led him from Australia to the birth of ... press interchange, Tolga Umar, CEO and Founder of CARE ...
(Date:3/3/2015)... March 03, 2015 Dan E. Chambers, an ... special focus on capital crimes, recently spoke on the radio ... trial. The hosts of the Independent Journal Review radio show ... working first as a prosecutor and now as a criminal ... decisions made in the trial and sentencing of this high-profile ...
(Date:3/3/2015)... 04, 2015 The report “Alopecia – ... therapeutic development for Alopecia. Alopecia is the loss of ... main types of alopecia. Causes for alopecia include aging, ... alopecia may include male pattern hair loss, female diffuse ... can be classified as focal or diffuse and by ...
Breaking Medicine News(10 mins):Health News:Want to Succeed in Medical Technology? Don't Innovate in a Vacuum 2Health News:Want to Succeed in Medical Technology? Don't Innovate in a Vacuum 3Health News:Borrower Accuses Mortgage Lenders of Racketeering in Forcing Insurance on Homeowners 2Health News:CARE Surrogacy Center Mexico Conducts Candid Interview with Australian Father of Twins 2Health News:CARE Surrogacy Center Mexico Conducts Candid Interview with Australian Father of Twins 3Health News:Dan E. Chambers Gives Radio Interview Providing Insights into American Sniper Guilty Verdict 2Health News:Dan E. Chambers Gives Radio Interview Providing Insights into American Sniper Guilty Verdict 3Health News:Alopecia Therapeutics Drugs and Companies Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com 2Health News:Alopecia Therapeutics Drugs and Companies Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com 3Health News:Alopecia Therapeutics Drugs and Companies Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com 4
... ... technology shows its latest UV-LED curing systems for UV printing applications in Guangzhou. , ... (PRWEB) March 8, 2010 -- Printing ... evolution of UV-LED curing technology from Phoseon for UV printing applications . The Phoseon ...
... three early-stage breast cancer patients who received genomic testing ... fully understand their discussions with physicians about their test ... four experienced distress when receiving their test results. ... of the American Cancer Society, the findings suggest there ...
... ... ... , , ... WASHINGTON , March ...
... ... Sponsors for the 2010 Cinco de Mayo Half Marathon and the 12th Annual “Reaching for ... ... Pediatric Cancer Research Foundation (PCRF) announced the official sponsors for the annual “Reaching for ...
... ... ... ... ...
... tips to prevent early tooth decay, damage , SATURDAY, March ... children,s teeth a healthy start is to begin dental care ... for keeping kids, teeth in tip-top shape: , Visit ... six months of the eruption of a child,s first tooth, ...
Cached Medicine News:Health News:Phoseon Technology Continues Worldwide Rollout of UV-LED Curing Systems with Attendance at Printing South China 2010 2Health News:Improvements needed in genomic test result discussions 2Health News:Illinois State Senator Cullerton Recognized for Advocacy Work on Mental Health Issues 2Health News:Illinois State Senator Cullerton Recognized for Advocacy Work on Mental Health Issues 3Health News:Illinois State Senator Cullerton Recognized for Advocacy Work on Mental Health Issues 4Health News:Sponsors for the 2010 Pediatric Cancer Research Foundation &#8220;Reaching for the Cure&#8221; Annual Cinco de Mayo Run/Walk Fundraising Event 2Health News:Sponsors for the 2010 Pediatric Cancer Research Foundation &#8220;Reaching for the Cure&#8221; Annual Cinco de Mayo Run/Walk Fundraising Event 3Health News:The Pentagon Tragedy: Mental Illness, Violence and What Reporters Should Ask 2Health News:The Pentagon Tragedy: Mental Illness, Violence and What Reporters Should Ask 3Health News:The Pentagon Tragedy: Mental Illness, Violence and What Reporters Should Ask 4Health News:The Pentagon Tragedy: Mental Illness, Violence and What Reporters Should Ask 5Health News:Protect Your Baby's Smile 2
... patented Orion incorporates superior optics in a ... The fully adjustable headband, made of white ... on the brow, directing the spot along ... on the headband position the cable diagonally ...
... Bring the clarity of daylight into the ... Light Source. Designed for a variety of ... instruments, and video equipment - this light ... 300 watts (6,000o K) for superb tissue ...
CO 2 SMO-Capnograph/Pulse Oximeter...
... for an emergency situation, bedside monitoring or ... / Pulse Oximeter delivers accurate SpO 2 ... handheld monitor now contains Nellcors latest OxiMax ... OxiMax sensors. The NPB-75 monitor also features ...
Medicine Products: